Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J AAPOS ; 23(2): 102-104, 2019 04.
Article in English | MEDLINE | ID: mdl-30445145

ABSTRACT

Sialidosis is a rare lysosomal storage disease caused by an α-N-acetyl neuraminidase-1 deficiency due to mutations of the NEU1 gene (6p21). Disease severity varies among patients and is linked to the level of residual neuraminidase activity in vivo. At least 40 disease-causing mutations in the NEU1 gene have been reported. Sialidosis occurs in two main clinical variants: type I, the milder form of the disease, and type II, which is subdivided into congenital, infantile, and juvenile forms. We report the clinical, biochemical, and molecular characterization of a patient with infantile sialidosis type II. The abnormal urinary oligosaccharide profile is described for the first time. The genetic characterization of the patient showed two previously unreported missense mutations in the NEU1 gene: p.R78C (c.232C>T) and p.R290Q (c.869G>A).


Subject(s)
Mucolipidoses/genetics , Mutation, Missense/genetics , Neuraminidase/genetics , Female , Humans , Infant , Infant, Premature , Mucolipidoses/urine , Oligosaccharides/urine
2.
Rheumatol Int ; 35(5): 777-85, 2015 May.
Article in English | MEDLINE | ID: mdl-25656443

ABSTRACT

Uveitis associated with juvenile idiopathic arthritis (JIA) typically involves the anterior chamber segment, follows an indolent chronic course, and presents a high rate of uveitic complications and a worse outcome as compared to other aetiologies of uveitis. Disease assessment, treatment, and outcome measures have not been standardized. Collaboration between pediatric rheumatologists and ophthalmologists is critical for effective management and prevention of morbidity, impaired vision, and irreparable visual loss. Although the Standardization of Uveitis Nomenclature Working Group recommendations have been a great advance to help clinicians to improve consistency in grading and reporting data, difficulties arise at the time of deciding the best treatment approach in the individual patient in routine daily practice. For this reason, recommendations for a systematized control and treatment strategies according to clinical characteristics and disease severity in children with JIA-related uveitis were developed by a panel of experts with special interest in uveitis associated with JIA. A clinical management algorithm organized in a stepwise regimen is here presented.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Algorithms , Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/complications , Mydriatics/therapeutic use , Uveitis/drug therapy , Abatacept/therapeutic use , Adalimumab/therapeutic use , Administration, Ophthalmic , Antibodies, Monoclonal, Humanized/therapeutic use , Child , Child, Preschool , Cooperative Behavior , Disease Management , Humans , Infliximab/therapeutic use , Methotrexate/therapeutic use , Ophthalmology , Practice Guidelines as Topic , Rheumatology , Severity of Illness Index , Uveitis/complications , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL
...